Pharma giant Novo licenses Chinese weight-loss drug
Novo’s agreement with Hengrui Pharma, which struck an even bigger deal with GSK last year, highlights the rapid advances in China’s cutting-edge biotech sector. Danish pharma giant Novo licensed a weight-loss treatment developed by a Chinese firm, highlighting advances in China’s increasingly cutting-edge biotech secto